

Claims

1. Use of an antibody specific for CD19 in the manufacture of a medicament for treating a B cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or B cell acute lymphoblastic leukemia, wherein the medicament is to be administered in combination with Idelalisib, and wherein said antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

2. The use according to claim 1, wherein the antibody comprises a variable heavy chain of the sequence
EVQLVESGGGLVKPGGSLKLSAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSIS
TAYMELSSLRSEDAMYYCARGTYYYGTRVFDYWGGQGLTVTVSS (SEQ ID NO: 10) and a variable light chain of the sequence
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFT
LTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).

3. The use according to claim 1 or claim 2, wherein the antibody comprises a heavy chain constant domain of the sequence
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQ
TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQ
FNWYVDGVEVHNAKTKPREEQFNSTFRVVSFLTVDVHQLDNLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYT
LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPMLDSGGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12).

4. The use according to any one of the preceding claims, wherein the antibody comprises a light chain constant domain of the sequence
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
STYLSSTLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC (SEQ ID NO: 13).

5. The use according to any one of the preceding claims, wherein said antibody specific for CD19 and Idelalisib are to be administered separately.
6. The use according to claim 5, wherein said antibody specific for CD19 and Idelalisib are to be administered separately physically.
7. The use according to claim 5, wherein said antibody specific for CD19 and Idelalisib are to be administered separately in time.
8. The use according to any one of claims 1-4, wherein said antibody specific for CD19 and Idelalisib are to be administered together.
9. The use according to any one of claims 1-4, wherein Idelalisib is to be administered prior to administration of the antibody specific for CD19.
10. The use according to any one of claims 1-4, wherein Idelalisib is to be administered after administration of the antibody specific for CD19.
11. The use according to any one of claims 1-4, wherein Idelalisib and the antibody specific for CD19 are to be administered simultaneously.
12. The use according to any one of claims 1 to 11 for treating a B cell non-Hodgkin's lymphoma , wherein the B cell non-Hodgkin's lymphoma is follicular lymphoma.
13. The use according to any one of claims 1 to 11 for treating a B cell non-Hodgkin's lymphoma , wherein the B cell non-Hodgkin's lymphoma is small lymphocytic lymphoma.
14. The use according to any one of claims 1 to 11 for treating a B cell non-Hodgkin's lymphoma , wherein the B cell non-Hodgkin's lymphoma is mucosa-associated lymphoid tissue lymphoma.

15. The use according to any one of claims 1 to 11 for treating a B cell non-Hodgkin's lymphoma , wherein the B cell non-Hodgkin's lymphoma is marginal zone lymphoma.

16. The use according to any one of claims 1 to 11 for treating a B cell non-Hodgkin's lymphoma , wherein the B cell non-Hodgkin's lymphoma is diffuse large B cell lymphoma.

17. The use according to any one of claims 1 to 11 for treating a B cell non-Hodgkin's lymphoma , wherein the B cell non-Hodgkin's lymphoma is Burkitt's lymphoma.

18. The use according to any one of claims 1 to 11 for treating a B cell non-Hodgkin's lymphoma , wherein the B cell non-Hodgkin's lymphoma is mantle cell lymphoma.

19. The use according to any one of claims 1 to 11 for treating chronic lymphocytic leukemia.

20. The use according to any one of claims 1 to 11 for treating B cell acute lymphoblastic leukemia.